You are here

Article Text

Article menu

Download PDFPDF

Poster/ePoster Sessions
01. Cervical cancer
#633 Survival nomograms neoadjuvant chemotherapy radical surgery cervical cancer : the UNDERSEA app
Free
  1. Claudia Marchetti1,
  2. Francesca De Felice2,
  3. Innocenza Palaia3 and
  4. Giovanni Scambia4
  1. 1Department of Woman’s and Child Health and Public Health Sciences, Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Catholic University of the Sacred Heart, Rome, Italy, Rome, Italy
  2. 2Department of Radiotherapy, Policlinico Umberto I, Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, Italy
  3. 3Department of Gynecological, Obstetrical and Urological Sciences, Sapienza University of Rome, Policlinico Umberto I, Rome, Italy
  4. 4Department of Woman’s and Child Health and Public Health Sciences, Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Catholic University of the Sacred Heart, Rome, Italy, Rome, Italy, Rome, Italy

Abstract

Introduction/Background Cervical cancer (CC) is one of the leading cancer by incidence/mortality in women worldwide. Highest incidence/mortality rates are recorded in low-income countries, including sub-Saharan-Africa, Melanesia, South-America and South-Eastern-Asia. This disproportionately in incidence/mortality rates compared to transitioned countries reflects the effective global cancer services variation.

Surgery, radiotherapy and chemotherapy in an integrated approach are necessary to treat CC as part of a management of evidenced-based effective care. These approaches aren’t interchangeable, but complementary and an increasing number of patients is best treated with at least two modalities. Around the world, there are still severe limitations in access to cancer care and especially radiotherapy services are scarce. To overcome regional and global large disparity, ASCO includes i) definitive radiotherapy with concurrent cisplatin-based chemotherapy and ii) neoadjuvant chemotherapy followed by radical surgery (NACT+S) as evidence-based resource-stratified recommendations on invasive CC management.

We have created the sUrvival Nomograms neoaDjuvant chEmotherapy Radical Surgery cErvical cAncer (UNDERSEA) application (app), an user-friendly app specifically designed for invasive CC patients candidate to NACT+S (http://undersea.app).

Abstract #633 Figure 1
Abstract #633 Figure 1

Undersea app

Methodology UNDERSEA app is a visualization tool of the results of an observational study of locally advanced CC patients treated with NACT+S. Statistical analysis was performed with R-Studio0.98.1091-software and web-app using Angular15.

Results UNDERSEA app is free, clean and quick to use. It estimates 2-year progression-free survival and 5-year overall survival rates, according to patient‘s relevant clinical and pathological prognostic factors, including age, tumor histology, lymphovascular space invasion, pathological locoregional lymph-nodes and pathological parametria status(figure 1).

Conclusion Thanks to its functionality and portability, UNDERSEA app offers an adequate web-based instrument able to estimate survival outcomes for cancer control. UNDERSEA app should be an example of successful efficient and effective care delivery around the world. The hope is to help clinicians in daily clinical practice to build an evidenced-based critical care and derive the best benefit for patients.

Disclosures Prof Scambia and Marchetti have potential conflict(s) of interest. Prof Palaia and De Felice have no potential conflict of interest to report.

http://dx.doi.org/10.1136/ijgc-2023-ESGO.169

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.